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Introduction
Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially cura-
tive treatment for a wide range of hematologic malignancies.1,2 Its anti-tumor activ-
ity relies in large part on immune-mediated graft-versus-leukemia (GvL) effects.3,4
However, donor immune cells contained in the graft can also target healthy host
tissues causing graft-versus-host disease (GvHD).5 GvHD can be divided into two
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Allogeneic hematopoietic stem cell transplantation is increasinglyused as treatment for patients with life-threatening blood diseases.Its curative potential is largely based on immune-mediated graft-
versus-leukemia effects caused by donor T cells contained in the graft.
Unfortunately, donor T cells are also the cause of graft-versus-host dis-
ease. The vast majority of human leukocyte antigen-matched allogeneic
hematopoietic stem cell transplants are nowadays carried out with
peripheral blood stem cells as the stem cell source. In comparison with
bone marrows, peripheral blood stem cells contain more hematopoietic
stem/progenitor cells but also one log more T cells. Consequently, the use
of peripheral blood stem cells instead of bone marrow has been associat-
ed with faster hematologic recovery and a lower risk of relapse in
patients with advanced disease, but also with a higher incidence of
chronic graft-versus-host disease. These observations have been the basis
for several studies aimed at assessing the impact of immunoregulation
with anti-thymocyte globulin on transplantation outcomes in patients
given human leukocyte antigen-matched peripheral blood stem cells
from related or unrelated donors. After a brief introduction on anti-thy-
mocyte globulin, this article reviews recent studies assessing the impact
of anti-thymocyte globulin on transplantation outcomes in patients given
peripheral blood stem cells from human leukocyte antigen-matched relat-
ed or unrelated donors as well as in recipients of grafts from human
leukocyte antigen haploidentical donors.
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syndromes, acute GvHD which is an inflammatory dis-
ease causing maculopapular erythematous rash, gastroin-
testinal symptoms, and/or cholestatic hepatitis, and
chronic GvHD which generally occurs beyond day 100, is
non-inflammatory, and shares many clinical features with
autoimmune diseases.6 Acute GvHD can be further divid-
ed into classical acute GvHD occurring within the first 100
days after transplantation, and late acute GvHD occurring
later.7,8 Chronic GvHD can also be subdivided, in this case
between classical chronic GvHD in which only typical
signs of chronic GvHD are present, and overlap syndrome
in which typical manifestations of both acute and chronic
GvHD coexist.7,8 While chronic GvHD has been associat-
ed with GvL effects,3,8-11 it is also the leading cause of mor-
tality/morbidity in long-term transplant recipients12,13 and
impairs quality of life.
Although the pathogeneses of acute and chronic GvHD
are distinct and involve several types of cells,5,14 donor T
cells play a pivotal role in both syndromes as demonstrat-
ed by the very low incidence of GvHD observed when
profound ex vivo T-cell depletion is performed,15 even in
the HLA-mismatched setting.16
The vast majority of HLA-matched allogeneic HCT per-
formed as treatment for acute leukemia in 2013 were car-
ried out with peripheral blood stem cells (PBSC) as the
stem cell source.17 The use of PBSC instead of bone mar-
row (BM) in patients receiving grafts from HLA-matched
donors has been associated with faster hematologic recov-
ery and a lower risk of relapse in patients with advanced
disease (due to greater GvL effects), but also with higher
incidences of each of severe acute and extensive chronic
GvHD.18-20 These observations served as the basis for stud-
ies combining the use of PBSC with in vivo T-cell depletion
of the graft with the aim of benefiting from the faster
engraftment associated with the use of PBSC without
exposing patients to high risks of severe GvHD. In this
article, after briefly discussing mechanisms of action of the
different brands of anti-thymocyte globulin (ATG), we
review recent studies assessing the impact of immunoreg-
ulation with ATG on transplantation outcomes in patients
given PBSC from HLA-matched donors as well as in those
given grafts (PBSC plus granulocyte colony-stimulating
factor-mobilized BM) from HLA-haploidentical donors,
and propose indications for the use of ATG in those set-
tings.
Anti-thymocyte globulin 
Three preparations of ATG are currently available (Table
1).21 ATGAM (ATG-h) consists of polyclonal IgG obtained
from hyperimmune sera of horses immunized with
human thymic cells. The two other brands of ATG consist
of polyclonal IgG obtained from hyperimmune sera of
rabbits immunized either with human thymocytes recov-
ered from patients undergoing cardiac surgery
(Thymoglobuline, ATG-T) or with the human Jurkat
leukemic T-cell line (which was derived from the periph-
eral blood of a 14-year old boy suffering from acute T-cell
leukemia22) [ATG Fresenius/Neovii (ATG-F)]. Although
ATG-h is still currently used for in vivo T-cell depletion in
the USA, two prospective randomized studies (including
one performed almost 4 decades ago) failed to demon-
strate its efficacy at preventing acute or chronic GvHD
after HLA-matched BM transplantation (BMT).23,24
Furthermore, a retrospective study from the Brazilian
National Cancer Institute in a cohort of 40 patients with
aplastic anemia receiving BMT from HLA-identical sib-
lings observed higher incidences of grade II-IV acute
GvHD (35% versus 0%, P=0.009) and moderate/severe
chronic GvHD (3-year rate: 34% versus 0%, P=0.04) in the
20 patients conditioned with cyclophosphamide plus
ATG-h (90 mg/kg total dose) than in those conditioned
with cyclophosphamide plus ATG-T (8 mg/kg total
dose).25 These findings might be due to the fact that, in
comparison to rabbit ATG, ATG-h induces less profound
and less durable lymphopenia, even if it is administered at
higher doses.25,26 
Antigens targeted by ATG-T have been well described
and include antigens expressed on T cells (such as CD2,
CD3, CD4, CD7, or CD8), B cells, natural killer cells,
macrophages and dendritic cells, as well as HLA class 1
and HLA-DR.27 Recognition by ATG-T of B cells and den-
dritic-cell antigens can also be attributed to the presence of
antigen-presenting cells, thymic stromal cells and B cells in
thymus fractions, although they are composed mainly of
T cells.27 Furthermore, ATG-T also contains antibodies tar-
geting antigens involved in cell adhesion and cell traffick-
ing, as well as antigens involved in inflammation, apopto-
sis and cell proliferation.27 Since ATG-F is produced by
immunizing rabbits with a homogenous Jurkat cell line,
and since during ATG-F (but not ATG-T) production rab-
bit IgG are adsorbed on human placental cells in addition
to adsorption on human erythrocytes, the spectrum of
antigens recognized by ATG-F is narrower than that rec-
ognized by ATG-T. For example, ATG-F does not contain
or contains significantly fewer antibodies directed against
CD3, CD4 or HLA-DR28,29 (Figure 1). However, in contrast,
compared to ATG-T, ATG-F contains more antibodies
directed against CD107 (an antigen expressed on T cells
during degranulation following antigenic stimulation).29
Competitive binding experiments have demonstrated that
ATG-T has stronger reactivity than ATG-F to activated
peripheral blood mononuclear cells.28 Furthermore, com-
In vivo T-cell depletion with ATG
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Table 1. Types of ATG. 
Name Type of antibodies Lympho-depletion GvHD prevention 
in vivo (total dose administered)
Antithymocyte globulin (ATG)
ATGAM (ATG-h) Polyclonal IgG from horses immunized with human thymocytes +/- –24*
ATG-Thymoglobuline (ATG-T)   Polyclonal IgG from rabbits immunized with human thymocytes + +
(2.5-10 mg/kg)
ATG-Fresenius / Neovii (ATG-F) Polyclonal IgG from rabbits immunized with human Jurkat + +
T leukemia cell line (15-60 mg/kg)
*Champlin et al.24
plement-mediated cytotoxic effects of ATG-T on periph-
eral blood mononuclear cells were stronger than those
mediated by ATG-F28 and ATG-T induced dendritic-cell
apoptosis more effectively than similar doses of ATG-F.30
Consequently, doses of ATG given for GvHD prohylaxis
have been typically higher for ATG-F (15-60 mg/kg) than
for ATG-T (2.5-10 mg/kg) (Table 1).
After in vivo infusion, all forms of ATG induce depletion
of both T and antigen-presenting cells by complement-
dependent lysis or antibody-dependent cellular cytotoxic-
ity, apoptosis of activated T cells, and maintenance of den-
dritic cells in a tolerogeneic state.27 Furthermore, rabbit
(but not horse) ATG induces the generation of regulatory
T cells (Treg), both in vitro and in vivo.31-33 This is clinically
relevant given accumulating evidence showing an impor-
tant role for Treg in GvHD prevention after allogeneic
HCT.34-37
The next paragraphs review the impact of both forms of
rabbit ATG on transplantation outcomes in various trans-
plantation settings. However since there has been no con-
trolled head-to-head comparison between ATG-T and
ATG-F reported thus far in the allogeneic HCT setting,
one should be cautious when extrapolating data from
medical literature referring to one of these two drugs. 
Role of rabbit anti-thymocyte globulin in
patients given HLA-matched peripheral blood
stem cells after myeloablative conditioning
Pharmacokinetics of anti-thymocyte globulin and
impact of post-transplant anti-thymocyte globulin
serum levels on transplantation outcomes
Several studies have assessed ATG pharmacokinetics
after PBSC transplantation. These studies demonstrated
that residual total rabbit IgG levels or residual free T-cell-
specific rabbit IgG levels were each influenced by the dose
of ATG administered, although there was a considerable
inter-patient variability. In detail, Forcina et al. assessed
specific ATG-F pharmacokinetics in 22 patients who
underwent allogeneic HCT after a myeloablative condi-
tioning combining fludarabine and treosulfan.38 ATG-F
was administered at a dose of either 10 mg/kg/day (n=17)
or 20 mg/kg/day (n=5) on days -4, -3 and -2 before trans-
plantation. T-cell-specific rabbit IgG levels peaked at the
end of the last dose of ATG-F administration and were
four times higher in patients given the 20 mg/kg dose.
These differences persisted on day 0. Furthermore, while
patients given the 10 mg/kg dose reached sub-therapeutic
specific rabbit IgG levels on day +10 after transplantation,
those given the 20 mg/kg dose kept supra-therapeutic spe-
cific rabbit IgG levels beyond day +21 after the allogeneic
transplant.
Waller et al. assessed ATG-T pharmacokinetics in 19
patients with high-risk hematologic malignancies who
received CD34+-selected, lymphocyte-depleted PBSC
from partially HLA-matched related donors.39 ATG-T was
administered at a dose of 2.5 mg/kg/day (n=2, 10 mg/kg
total dose) or 1.5 mg/kg/day (n=17, 6 mg/kg total dose) for
4 consecutive days (the last 4 days of the conditioning reg-
imen). In comparison to patients given ATG-T at the 6
mg/kg total dose, those receiving a total dose of 10 mg of
ATG-T had comparable total rabbit IgG levels (77±14 ver-
sus 62±22 μg/mL, P=0.4) but higher specific rabbit IgG lev-
els on day 0 (25±8 versus 9±6 μg/mL, P=0.002).
Furthermore, the number of days required to reach infra-
therapeutic levels of specific rabbit IgG levels was 35±4
versus 17±9 days in patients given 10 or 6 mg/kg ATG-T
total dose, respectively (P=0.01).   
Remberger et al. prospectively assessed total ATG-T lev-
els in 76 patients given PBSC (n=60) or BM (n=16) after
myeloablative (n=37) or reduced-intensity (n=39) condi-
tioning.40 All patients received ATG-T at the dose of 2
mg/kg/day for 2-4 days (total dose 4 mg/kg to 8 mg/kg)
with the last dose given on day -1. Day 0 and 7 total rab-
bit IgG levels were 49 and 26 μg/mL, respectively in
patients receiving 6 mg/kg ATG-T total dose (n=46), versus
63 and 42 μg/mL respectively in patients receiving 8
mg/kg ATG-T total dose (n=26). The estimated half-life of
total rabbit IgG was 9 days. 
Analyses of the impact of ATG serum levels on trans-
plantation outcomes were pioneered by the group of Jan
Storek at the University of Calgary. This group correlated
ATG serum levels on days 0 (immediately before graft
infusion), 7 and 28 after allogeneic HCT with transplanta-
tion outcomes in a large cohort of patients conditioned
with a myeloablative regimen combining fludarabine (250
mg/m2 total dose), busulfan [12.8 mg/kg IV – pharmacoki-
netics adjusted - total dose], and ATG-T [given at the
doses of 0.5 mg/kg on day −2, 2.0 mg/kg on day −1, and
2.0 mg/kg on day 0 (total, 4.5 mg/kg)]. Patients with
leukemia also received 4 Gy total body irradiation. The
authors demonstrated that high levels of serum ATG-T on
days 7 and 28 each correlated with a low incidence of
acute and chronic GvHD, but also with a high incidence
of post-transplant lymphoproliferative disorder.41,42 In con-
trast, high ATG levels on day 0 were associated only with
a low incidence of chronic GvHD.42 Importantly, no asso-
ciations were observed between ATG levels and relapse or
non-relapse mortality. Subsequently, the same group
demonstrated that high levels of ATG-T specificities capa-
ble of binding to Treg and invariant natural killer T cells on
day 7 were associated with a low incidence of relapse.43
Impact of anti-thymocyte globulin on immune recovery
The first large study assessing the impact of ATG-T on
immune recovery was reported by Bosch et al.44 The
F. Baron et al.
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Figure 1. Quantification of ATG antibodies targeting specific human antigens.
(adapted from Table 1 from Popow et al.29) Black bars represent ATG-F data and
white bars ATG-T data. 
authors compared immune recovery the first 2 years after
transplantation in patients given PBSC either in Calgary
after the fludarabine/busulfan/ATG-T regimen described
above (n=125), or in Seattle after conditioning with
cyclophosphamide 120 mg/kg and 12 Gy total body irra-
diation (and no ATG) (n=46). Post-grafting immunosup-
pression and flow-cytometry analyses were similar in the
two cohorts of patients. Main observations were that, 1
month after allogeneic HCT, ATG-T patients had lower
counts of B cells, as well as CD4+ and CD8+ T cells, while,
for at least 1 year after transplantation, counts of naïve and
memory CD4+ T cells as well as of naïve CD8+ T cells
remained lower in patients given ATG-T than in those not
given ATG. Comparable qualitative observations have
been recently made in a cohort of 65 patients given PBSC
after various myeloablative conditioning regimens at the
University of Liège and who were given ATG-F (45 mg/kg
total dose, n=37) or not (n=28).45
Non-randomized studies comparing anti-thymocyte
globulin versus no anti-thymocyte globulin
A number of phase II studies have assessed the impact
of rabbit ATG in patients given unmodified grafts after
myeloablative conditioning46-52 (Table 2). Collectively,
these studies suggested that ATG decreased the incidence
of grade III-IV acute and chronic GVHD without increas-
ing non-relapse mortality (some studies even found lower
non-relapse mortality with ATG), increased the incidence
of post-transplantation lymphoproliferative disorders, and
improved quality of life. A recent study from La Societe
Francophone de Greffe de Moelle et de Thérapie Cellulaire
(SFGM-TC) compared the impact of ATG according to
stem cell source (PBSC versus BM) in patients given grafts
from 10/10 HLA-matched unrelated donors following
myeloablative conditioning regimens. Data from 356
patients with acute myeloid leukemia or myelodysplastic
syndrome were included in the analyses. Among patients
In vivo T-cell depletion with ATG
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Table 2. Selected non-randomized study comparing myeloablative allogeneic stem cell transplantation outcomes in patients given ATG or not. 
Study N. of ATG patients/ Study design Main observations. 
N. of control patients In comparison to control patients, ATG patients had:
Unrelated donors
Zander et al.46 145 / 188 Retrospective analysis of CML patients Faster leukocyte enraftment (P<0.001)
given ATG-F (average dose 90 mg/kg) Lower incidence of grade III-IV acute GvHD  (P=0.03)
or not before unrelated BMT or PBSCT. Lower NRM (P=0.03)
A trend for higher relapse (P=0.09)
Better OS (P=0.03)
Schattenberg et al.47 34 / 22 Retrospective study in patients given Lower NRM (P=0.004)
ATG-T (8 mg or 16 mg/kg) or not before Better DFS (P=0.005)
partially TCD unrelated BMT. Better OS (P=0.002)
Yu et al.48 54 / 42 Retrospective study in patients given ATG-F Lower incidence of grade III-IV acute GvHD  (P=0.03)
(16 mg/kg) or not before related or Lower incidence of chronic GvHD  (P=0.002)
unrelated HCT.  Higher incidence of infections (P=0.02)
Better global quality of live (P<0.01)
Less fatigue (P<0.01)
Ratanatharathorn et al.50* 76 / 121 Retrospective study in patients given Lower incidence of grade III-IV acute GvHD (P=0.02)
ATG-T (4.5 mg/kg) or not before unrelated Lower incidence of chronic GvHD (P<0.001)
HCT (mainly PBSCT) Lower NRM (P=0.01)
Better OS (P=0.01)
Binkert et al.51 120 / 145 Retrospective study in patients given ATG-F Slower neutrophil engraftment (P<0.001)
(35 or 60 mg/kg) or not before related Higher EBV infection
(n=117) or unrelated (n=148) PBSCT Higher viral infection
Lower incidence of chronic GvHD (P=0.03)
Lower NRM and better OS with lower ATG doses
Ravinet et al.53 47 / 92 Retrospective study in patients given Lower incidence of grade III-IV acute GvHD (P=0.04)
ATG-T or not before unrelated PBSCT Lower incidence of chronic GvHD (P=0.03)
Higher GvHD-free/relapse-free survival (P<0.01)
Ravinet et al.53 64 / 153 Retrospective study in patients given No statistically significant impact of ATG on outcomes
ATG-T or not before unrelated BMT
Related donors
Bonifazi et al.52 47 / 146 Retrospective study of patients given ATG-F Lower incidence of extensive chronic GvHD (P=0.03)
(15 or 30 mg/ kg) before PBSCT from 
HLA-identical siblings
Wolschke et al.49* 79 / 159 Retrospective study in patients receiving Slower leukocyte enraftment (P=0.001)
PBSCT from sibling donors and given Higher incidence of PTLD (P=0.05)
ATG-F (median dose of 30 mg/kg) or not. Lower incidence of grade II-IV acute GvHD  (P=0.04)
Lower incidence of chronic GvHD  (P=0.002)
iTCD: in vivo T-cell depletion; ATG-T: ATG-Thymoglobuline; ATG-F: ATG-Fresenius/Neovii; Alem: alemtuzumab; BMT: bone marrow transplantation; HCT: hematopoietic cell trans-
plantation; PBSCT: peripheral blood stem cell transplantation; CML: chronic myeloid leukemia;GvHD: graft-versus-host disease; OS: overall survival; DFS: disease-free survival;
NRM: non-relapse mortality;  *also includes patients given grafts after reduced intensity conditioning.
given PBSC (n=139), those given ATG (n=47) had lower
cumulative incidences of grade III-IV acute GvHD (HR
0.17, P=0.04) and chronic GvHD (HR 0.31, P=0.03) in
comparison to those not given ATG.53 Interestingly, the
patients who received ATG had a significantly better
GvHD-free/relapse-free survival (HR 0.48, P<0.01) than
patients who did not. Notably, these correlations were not
statistically significant in the group of patients who
received BM as their source of stem cells (n=217). 
Anti-thymocyte globulin dose-finding study
The best dose of ATG to use in patients who have been
given PBSC after myeloablative conditioning has
remained undefined. In an effort to address this issue,
Deeg et al. performed a dose-finding study of ATG-T in
patients with myeloid malignancies given PBSC after tar-
geted busulfan plus cyclophosphamide conditioning.54
The starting dose of ATG-T was 4.5 mg/kg total dose (0.5
mg/kg on day -3, and 2 mg/kg on each of days -2 and -1)
and escalation was dependent on the occurrence of acute
GvHD on the one hand, and Epstein–Barr virus (EBV)
reactivation on the other hand. The authors identified a
total dose of 6 mg/kg as the highest tolerable dose (in term
of EBV reactivation). The incidences of grade II-IV acute
and extensive chronic GvHD were comparable in patients
given 4.5 or 6.0 mg/kg ATG-T, but were both lower in
ATG-T patients (n=56) than in concurrent control patients
(n=27) (50% versus 82% for grade II-IV acute GvHD, and
34% versus 82% for extensive chronic GvHD, respective-
ly). This study suggests that administration of ATG-T at a
total dose of 4.5 mg/kg to 6 mg/kg is safe and might suc-
cessfully prevent GvHD in patients receiving PBSC from
HLA-matched donors after myeloablative conditioning.
Randomized studies comparing anti-thymocyte globulin
versus no anti-thymocyte globulin
Four randomized studies have assessed the impact of
rabbit ATG on allogeneic HCT outcomes.55-58 None of
these studies was double-blinded and thus the possibili-
ty of a certain bias in the grading of GvHD cannot be
ruled out. 
- Unrelated donors
The first randomized study assessing the use of rabbit
ATG was carried out by the Gruppo Italiano Trapianti
Midollo Osseo (GITMO) in patients who underwent BMT
from unrelated donors after myeloablative conditioning.55
It is important to note that this study was performed
before HLA high-resolution typing was available. In a first
part of the study, 54 patients were randomized between
no ATG or ATG-T 7.5 mg/kg total dose, while in the sec-
ond part, 55 patients were randomized between no ATG
or ATG-T 15 mg/kg total dose (Table 3). Patients not given
ATG and those given 7.5 mg/kg ATG-T had similar inci-
dences of grade III-IV acute GvHD, while patients given
ATG-T 15 mg/kg had a lower incidence of grade III-IV
acute GvHD but also a higher incidence of infections.
Importantly, the incidence of extensive chronic GvHD
was significantly lower among the patients given ATG-T
7.5 mg (38%) and ATG-T 15 mg (41%) than among the
control patients (62%; P=0.04). However, ATG-T failed to
improve overall survival, even with a long follow-up.59
Finke et al. and Socie et al. conducted a phase III random-
ized study comparing standard GvHD prophylaxis with
cyclosporine and short-course methotrexate with or with-
out added ATG-F.56,60 The study included 201 patients who
underwent unrelated BMT (n=37) or PBSC transplantation
(n=164) after myeloablative conditioning. Patients were
randomized between ATG-F (20 mg/kg on days -3, -2 and
-1) or no ATG. The primary endpoint was grade III-IV
acute GvHD or death within the first 100 days after the
allogeneic HCT. Although the primary endpoint was not
statistically different between the two groups (P=0.13),
the study demonstrated that the patients given ATG had
lower incidences of grade II-IV acute GvHD (33% versus
51%, P=0.01),56 chronic GvHD (30% versus 60%,
P<0.001), and extensive chronic GvHD (12% versus 45%,
P<0.001).60 However, ATG significantly delayed both neu-
trophil engraftment (26 versus 19 days to achieve 1x109
neutrophils/L, P<0.001) and platelet engraftment (20 versus
37 days to achieve 50x109 platelets/L, P<0.001), while five
patients in the ATG arm but none in the control arm
developed a post-transplant lymphoproliferative disor-
der.56 Importantly, although there was only a statistically
non-significant survival advantage for ATG patients (at 3
years 55% versus 43%, P=0.39), the 3-year probability of
being alive and free of immunosuppressive drugs was
three times higher among ATG patients than among con-
trol patients (53% versus 17%, P<0.001).60
Another randomized study in the unrelated allogeneic
HCT setting was recently reported by Walker et al.57 The
main inclusion criteria were HLA-matched or 1/8 single
HLA-mismatched unrelated donor, hematologic malig-
nancy, myeloablative conditioning or reduced intensity
conditioning (RIC), and PBSC or BM as the stem cell
source. The primary endpoint was freedom from GvHD
F. Baron et al.
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Table 3. Randomized studies of rabbit ATG as GvHD prevention in patients given allogeneic hematopoietic cell transplantation.  
N. of ATG brand / Acute GvHD Chronic GvHD Non-relapse Relapse Overall
patients total dose II-IV mortality survival
(mg/kg)
% ATG/ % % ATG/ % % ATG/ % % ATG/ % % ATG/ %
no ATG (P) no ATG (P) no ATG (P) no ATG (P) no ATG (P)
Bacigalupo et al.55 54 T / 7.5 69 / 72 (0.6) 38 / 65 (0.08) 43 / 39 (0.7)a 10 / 12 (0.6)a 56 / 55 (0.8)a
Bacigalupo et al.55 55 T / 15 37 / 79 (0.001) 41 / 59 (0.3) 47 / 49 (0.9)b 36 / 18 (0.8)b 43 / 43 (0.8)b
Finke & Socie et al.56 60 201 F / 60 33 / 51 (0.01) 30 / 60 (<0.001)a 19 / 34 0.18)a 33 / 28 (0.5)a 55 / 43 (0.39)a
Kroger et al.58 155 F / 30 11 / 18 (0.13) 32 / 69 (<0.001)c 14 / 12 (0.6)c 32 / 26 (0.17)c 74 / 78 (0.5)c
Walker et al.57 196 T / 4.5 50 / 65 (0.01)d 22 / 33 (0.06)b 23 / 24 (NS)b 11 / 16 (NS)b 75 / 65 (0.24)b
aat 3 years; bat 1 year; cat 2 years; dgrade I-IV at day 100. F: ATG-Fresenius; T: ATG-Thymoglobuline.
and systemic immunosuppressive treatment without
resumption up to 12 months after transplantation. Of 203
randomized patients, 196 were eligible. These included 99
patients randomized to ATG-T (0.5 mg/kg on day -2 and
2 mg/kg on days -1 and +1), and 97 randomized to no
ATG. Sixty-seven percent of patients received myeloabla-
tive conditioning (and 33% RIC), and in 88% of cases
peripheral blood was the stem cell source. The main
observations were that the primary endpoint was met in
37% of patients given ATG versus 16% of the patients not
given ATG (P<0.001). Furthermore, ATG-treated patients
had a significantly lower incidence of grade I-IV acute
(50% versus 65% at 100 days, P=0.01) and chronic (22 ver-
sus 33, P=0.06) GVHD, without an increased risk of
relapse (11% versus 16% at 1 year). However, there was a
higher incidence of EBV reactivation among the patients
given ATG (33% versus 3%). Finally, there was a non-sta-
tistically significant survival advantage for the ATG-treat-
ed patients (at 1 year: 75% versus 65%, P=0.2). Longer fol-
low-up is needed to determine the impact of ATG on late
relapses and on late non-relapse deaths.
The study by Walker et al. also prospectively assessed
the impact of ATG-T on quality of life.57 Patients assigned
to the ATG-T arm had better Atkinson Life Happiness
Scale Scores at 12 months and lower chronic GvHD symp-
tom burden (assessed by the Lee scale) at 6 and 12 months
after transplantation. These data suggest a beneficial
impact of ATG on quality of life.
- HLA-identical sibling donors
The impact of ATG on transplantation outcomes has
recently been tested in the setting of PBSC transplantation
from HLA-identical sibling donors in patients suffering
from acute leukemia in complete remission.58 One hun-
dred fifty-five eligible patients were randomized between
ATG-F (n=83, administered at 10 mg/kg/day on days -3, -
2 and -1) or no ATG (n=72). The 2-year cumulative inci-
dence of chronic GvHD (primary endpoint of the study)
was 32% in ATG patients versus 69% in controls
(P<0.001). Other observations included slower leukocyte
and platelet engraftment in ATG patients, while other
transplantation outcomes (infections, acute GvHD,
relapse incidence, non-relapse mortality, overall survival
and progression-free survival) were not statistically signif-
icantly different between the two groups of patients
(Table 3). Since this study only included patients in com-
plete remission at the time of transplantation, further
studies are needed to assess the impact of ATG in patients
with advanced leukemia.
Role of rabbit anti-thymocyte globulin in
patients given HLA-matched peripheral blood
stem cells after reduced-intensity conditioning
RIC allogeneic HCT relies mainly on GvL effects for
tumor eradication.61-63 The biology of GvL effects remains
poorly defined but has been thought to involve reactions
to polymorphic minor histocompatibility antigens
expressed either specifically on hematopoietic cells or
more widely on a number of tissue cells.64 As mentioned
above, several studies have demonstrated a close relation-
ships between GvHD and GvL responses after RIC or
low-intensity immunosuppressive conditioning,8-11,65 sug-
gesting that the use of in vivo T-cell depletion might be
harmful in that setting. However achievement/mainte-
nance of complete remission has been observed in many
patients given grafts after RIC/low-intensity conditioning
who did not develop GvHD,8-11,66 suggesting that clinical
manifestations of GvHD are not universally required in
order to achieve/maintain remissions. 
Unfortunately, the randomized studies on the use or not
of ATG were conducted mostly in patients undergoing
myeloablative transplants. However, 33% of the patients
included in the study by Walker et al. described above
were given RIC or low intensity conditioning and, inter-
estingly, the relapse incidence was similar between
patients who were given ATG (n=33) and those who were
not (n=31) also in this subgroup of patients.57 Since it is
hazardous to draw definitive conclusions based on data
from a subgroup analysis of 64 patients, we also have to
rely on phase II prospective and registry studies to esti-
mate the impact of ATG specifically in the RIC allogeneic
HCT setting.  
Data from single center studies
The Marseille group conducted a number of phase II
studies aimed at optimizing ATG-T dosing in patients
given grafts after RIC conditioning.67-70 They used the RIC
regimen combining fludarabine and busulfan.61 Post-graft-
ing immunosuppression consisted of cyclosporine alone in
the case of HLA-identical sibling donors, or cyclosporine
plus mycophenolate mofetil in the case of unrelated
donors. In a first study, they compared transplantation
outcomes in patients given high (7.5-10 mg/kg total dose,
n=46) or low (2.5 mg/kg total dose, n=55) dose ATG-T
before transplantation from HLA-identical siblings.
Incidences of grade II-IV acute GvHD (P=0.001) and
chronic GvHD (P=0.02) were significantly lower in
patients given the higher dose of ATG. However, this ben-
efit was offset by a higher incidence of relapse in the
group of patients given high-dose ATG.
In a second study, the authors retrospectively compared
ATG-T 2.5 mg/kg total dose (n=124) to ATG-T 5 mg/kg
total dose (n=105).68 All patients received PBSC from
either HLA-identical siblings (n=187) or unrelated donors
(n=42). The main observations were that patients given 5
mg of ATG had lower incidences of grade II-IV acute
GvHD (23% versus 42%, P=0.002) and chronic GvHD
(35% versus 69%, P<0.001) than those given 2.5 mg/kg
ATG. However, importantly, other transplantation out-
comes (relapse, non-relapse mortality, overall survival and
leukemia-free survival) were comparable between the two
groups of patients. Similar observations were made when
the analyses were restricted to patients transplanted as
treatment for myeloid malignancies.69
Investigators from Karolinska University performed a
retrospective study including data from 110 patients given
unrelated PBSC (n=95) or BM (n=15) following
chemotherapy-based RIC.71 Transplantation outcomes
were compared between patients given a total ATG-T
total dose of 6 mg/kg (n=66) or 8 mg/kg (n=44). The
authors observed a higher incidence of relapse (P=0.04)
and lower leukemia-free survival rate (P=0.04) in patients
given the higher dose of ATG. 
More recently, Langston et al. reported the results of a
retrospective study of 85 patients given PBSC (n=74) or
BM (n=11) from unrelated donors at Emory University
after fludarabine plus melphalan conditioning.72 Patients
with 10/10 HLA-matched unrelated donors were not
given ATG (n=54), while patients given grafts from HLA-
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mismatched donors were given ATG-T 6 mg/kg total
dose. Remarkably, the authors observed comparable out-
comes in the two cohorts of patients, suggesting that the
addition of ATG was able to offset the negative impact of
HLA-mismatch without increasing the incidence of
relapse or infection. 
Data from registry studies
A first registry study assessing the impact of in vivo T-cell
depletion on outcomes in the RIC setting was reported by
Soiffer et al. on behalf of the Center for International Blood
and Marrow Transplant Research (CIBMTR).73 The study
included data from 1676 adult patients given BM (n=203)
or PBSC (n=1473) after various RIC regimens as treatment
for a heterogeneous group of hematologic malignancies.
Patients were divided into three groups: one group was
not given either ATG or alemtuzumab (controls, n=879),
one group was given ATG (n=584; including 160 patients
who received horse ATG and 405 patients who received
ATG-T at a median total dose of 7 mg/kg), and one group
was given alemtuzumab (n=213). In multivariate analyses,
in comparison to control patients, those given ATG had a
similar incidence of grade III-IV acute GvHD (HR 0.9,
P=0.2), a lower incidence of chronic GvHD (HR 0.7,
P<0.001), a higher incidence of non-relapse mortality (HR
1.3, P=0.01), and a higher incidence of relapse (HR 1.5,
P<0.001). This translated into significantly worse overall
survival (HR 1.3, P=0.002) and disease-free survival (HR
1.5, P<0.001) in patients given ATG. 
The Acute Leukemia Working Party (ALWP) of the
European Society for Blood and Marrow Transplantation
(EBMT) revisited this issue in a more homogeneous
cohort of 1,250 patients with acute myeloid leukemia in
first complete remission given PBSC from HLA-identical
siblings.74 A total of 554 patients did not receive any form
of in vivo T-cell depletion (control group), whereas ATG
and alemtuzumab were given in 444 and 252 patients,
respectively. In multivariate analyses, the use of ATG was
associated with a lower risk of chronic GvHD (HR=0.6,
P<0.001) and a lower risk of extensive chronic GvHD
(HR=0.5, P<0.001). Furthermore, in contrast to what was
observed in the CIBMTR study, ATG patients had a simi-
lar risks of relapse (HR=1.1, P=0.40) and non-relapse mor-
tality (HR=0.9, P=0.6), and similar overall survival
(HR=0.9, P=0.6) and leukemia-free survival (HR=1.0,
P=0.8) in comparison to control patients (Figure 2). The
impact of ATG on the risk of relapse and on leukemia-free
survival in the subgroup of patients transplanted following
F. Baron et al.
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Figure 2. Impact of ATG on transplantation outcomes in patients given grafts after reduced-intensity conditioning. (A) Forest plots showing the results of multivari-
ate analyses from two large registry studies assessing the impact of ATG on transplantation outcomes either in patients with various hematologic malignancies [study
from the Center for International Blood and Marrow Transplant Research (CIBMTR)73] or in patients with acute myeloid leukemia in first complete remission [study
from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)74]. (B) Relapse incidence and (C) progression-free sur-




a busulfan-based RIC is shown in Figure 2B,C. Within this
subgroup of patients, the relapse incidence was similar in
those given <6 mg/kg ATG and in those not given ATG
(HR=1.1, P=0.9), while there was a suggestion of a higher
incidence of relapses in patients given ATG at a dose ≥6
mg/kg (HR 1.4, P=0.08). 
Taken together, these phase II and registry study data
suggest that a total dose of ATG-T around 5 mg/kg might
be optimal in the RIC setting. This assumption should be
tested in an appropriate phase III trial with a uniform con-
ditioning regimen and post-grafting immunosuppression.75
Role of rabbit anti-thymocyte globulin 
in patients given HLA-matched peripheral 
blood stem cells after low-intensity
immunosuppressive conditioning
The impact of ATG has also been investigated in the set-
ting of PBSC transplantation following low-intensity
immunosuppressive conditioning. The Stanford group
developed a low-intensity conditioning regimen combin-
ing ATG-T (7.5 mg total dose given at the dose of 1.5
mg/kg from day -11 to day -7) and 8 Gy total lymphoid
irradiation in ten fractions followed by PBSC transplanta-
tion (TLI-ATG regimen).76,77 This conditioning allowed
sustained engraftment and GvL effects (mainly in patients
who achieved full donor T-cell chimerism) with a very
low incidence of GvHD.76,77 In murine models of transplan-
tation, this was achieved through Th2 polarization of
donor T cells by recipient invariant natural killer/T cells
(still present at transplantation given their relative resist-
ance to ionizing radiation),78 and through expansion of
donor Treg by recipient invariant natural killer/T cells.78
The Belgian Society of Hematology conducted a phase
II randomized study comparing low-intensity transplanta-
tion following a fludarabine plus 2 Gy total body irradia-
tion regimen (n=49) developed by the Seattle group or fol-
lowing TLI-ATG (n=45).79 The main observations were
that overall survival rates were comparable in the two
study arms (53% in patients treated with fludarabine and
total body irradiation versus 54% in TLI-ATG patients)
although the TLI-ATG patients had a significantly lower
incidence of moderate/severe chronic GvHD (18% versus
41%, P=0.02) but a higher risk of relapse/progression at 4
years (50% versus 22%, P=0.02). The low incidence of
chronic GvHD in TLI-ATG recipients could be attributed
in part to higher Treg /naïve CD4 T-cell ratios early after
transplantation.80 
Role of rabbit anti-thymocyte globulin in
patients given HLA-haploidentical peripheral
blood stem cells 
Although only 20-30% of patients have an HLA-identi-
cal sibling donor, virtually all patients have a potential
HLA-haploidentical donor. Historically, HLA-haploidenti-
cal transplants were performed by transplanting a “mega-
dose” of in vitro-selected CD34+ cells.81-83 This technique
resulted in extensive in vitro T-cell depletion that prevent-
ed severe GvHD but also affected immune reconstitution
leading to high incidences of both infections and disease
relapse/progression.84
Fortunately, several novel approaches have been devel-
oped in the last decades and have resulted in more favor-
able outcomes.85 These approaches include co-infusion of
megadoses of CD34+ cells with donor Treg and conven-
tional T cells at a 2:1 ratio,36 and T-cell-repleted HLA-hap-
loidentical transplantation with either high-dose post-
transplantation cyclophosphamide,86 or intensive phar-
macological immunosuppression including ATG. Using
the latter strategy, the Bejing group developed a protocol
combining granulocyte-colony-stimulating factor-mobi-
lized BM and PBSC, as well as administration of ATG-T
to prevent both graft rejection and GvHD.87 ATG-T was
administered from days -5 to -2 at the dose of either 2.5
mg/kg/day or 1.5 mg/kg/day. The conditioning regimen
consisted of cytarabine (4 g/m2/day on days -10 to -9),
busulfan (4 mg/kg/day orally or 3.2 mg/kg i.v. on days –8
to –6), cyclophosphamide (1.8 g/ m2/day on days -5 to -4),
or semustine (250 mg/m2 on day -3), while post-grafting
immunosuppression was obtained with cyclosporine,
mycophenolate mofetil, and short-course methotrexate.
The outcomes of 1,210 consecutive patients offered HLA-
haploidentical transplantation following this strategy
were reported recently. The incidence of grade III-IV
acute GvHD was 12%, while the 3-year cumulative inci-
dence of chronic GvHD was 50%. At 3 years, progres-
sion-free and overall survival rates were 67% and 70%,
respectively. 
The same group of authors recently reported the results
of a phase III non-inferiority trial investigating two doses
of ATG-T (6 mg/kg total dose versus 10 mg/kg total dose)
before infusion of granulocyte-colony-stimulating factor-
mobilized BM and PBSC from HLA-haploidentical
donors.88 The primary endpoint was the incidence of
grade III-IV acute GvHD. In comparison to patients given
ATG-T 10 mg/kg total dose, those given 6 mg/kg total
dose had a higher incidence of grade III-IV acute GvHD
(16% versus 4%, P=0.005). Furthermore, the 1.5-year
cumulative incidence of chronic GvHD was 65% versus
45% in the ATG-T 6 mg/kg and ATG-T 10 mg/kg groups,
respectively (P=0.01). However, the incidences of sep-
ticemia (5% versus 12%, P=NS), EBV reactivation (10%
versus 25% at 1 year, P<0.001) and post-transplant lym-
phoproliferative disorder (2% versus 8%, P=0.03) were
each lower in the ATG-T 6 mg/kg group than in the ATG-
T 10 mg/kg group. This could be attributed to slower
immune recovery in patients given ATG-T 10 mg/kg total
dose. Relapse, progression-free and overall survival rates
were similar in the two arms. 
The Milan group developed another protocol of HLA-
haploidentical transplantation. The study included 121
patients, most with advanced disease. The conditioning
regimen combined treosulfan (14 g/m2/day on days -6 to
-4) and fludarabine (30 mg/m2/day on days -6 to -2), and
post-grafting immunosuppression combining ATG-F 10
mg/kg on days -4 to -2, sirolimus and mycophenolate
mofetil.89 The incidence of grade III-IV acute GvHD was
22%, while the 2-year cumulative incidence of chronic
GvHD was 47%. At 3 years, the cumulative incidences of
non-relapse mortality, progression-free survival and over-
all survival were 31%, 20% and 25%, respectively.
Summary: possible indications for 
anti-thymocyte globulin in patients transplanted
with peripheral blood stem cells
In summary, three prospective randomized studies have
demonstrated that ATG decreases the incidence of chronic
GvHD without increasing the risk of relapse or non-relapse
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mortality in patients given HLA-matched related90 or unre-
lated PBSC after myeloablative conditioning.60 This sug-
gests that ATG might become a standard of care in that set-
ting (Table 4) although ATG has also been associated with
infusion reactions, delayed hematopoietic and immune
recovery, and increased risks of cytomegalovirus and EBV
infections. Potential limitations of these studies are that
they allowed different conditioning regimens (based on
total body irradiation or chemotherapy), that they included
patients with various risks of disease relapse, and that they
lacked statistical power to assess the impact of ATG on dis-
ease relapse in high-risk patients. Future phase III studies
should deal with these limitations and also, ideally, com-
pare ATG administration with new methods of GvHD pro-
phylaxis such as post-transplant cyclophosphamide.91
Another important comparison that should be addressed in
a phase III study is that between a combination of PBSC
with ATG versus BM without ATG.
In the RIC setting, a retrospective study from the
CIBMTR observed that in vivo T-cell depletion with ATG
increased the risk of relapse and decreased disease-free
survival in a cohort of patients transplanted for various
hematologic malignancies.73 However, several phase II
studies68,69 as well as a retrospective study by the ALWP of
the EBMT74 suggested that low doses of ATG efficiently
prevented chronic GvHD without impairing leukemia-
free or overall survival, while the use higher doses of ATG
(>6 mg/kg ATG-T) was associated with a higher risk of
relapse. Prospective randomized studies are thus needed
to confirm the impact of in vivo T-cell depletion on out-
comes specifically in the RIC setting.
Conclusions
Three brands of ATG are currently commercialized.
ATG-h (ATGAM) is currently available almost only in the
USA. ATG-h induces less lymphopenia than the two brands
of rabbit ATG.26 However, its impact on GvHD prevention
has remained uncertain and is not supported by data from
phase III studies. Although the two brands of rabbit ATG
(ATG-T and ATG-F) share some similarities (such as induc-
ing a profound and more durable lymphopenia than ATG-
h), they diverge by the nature and intensity of antigens rec-
ognized.29 Large studies comparing the impact of ATG-T
versusATG-F on immune recovery and post-transplant lym-
phoproliferative disorder are lacking. Consequently, data
observed with one rabbit ATG product cannot be automat-
ically extended to the other rabbit ATG formulation.
Proposed indications/doses for immunoregulation with
ATG in patients given PBSC from allogeneic donors are
summarized in Table 4. 
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Table 4. Proposed indications for immunoregulation with ATG in patients given PBSC from allogeneic donors.
Recommendation for ATG Dose and timing of ATG
Myeloablative PBSCT from matched sibling donors58 standard of care ATG-F 10 mg/kg/day on days -3, -2 and -1.
Myeloablative PBSCT from HLA-matchedunrelated donors56,60,57 standard of care ATG-F 20 mg/kg/day on days -3, -2 and -1*.
ATG-T 0.5 mg/kg on day -2 and 2 mg/kg on days -1 and +1.
RIC-PBSCT  fludarabine-busulfan68 recommended ATG-T 2.5 mg/kg/day on days -2 and -1.
Non-myeloablative PBSCT developmental /
HLA-haplo-identical stem cell transplantation (Bejing approach)88 standard of care ATG-T 2.5 mg/kg/day from days -5 to -2.
* some centers use smaller doses such as 15 mg/kg total dose.
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